Loading
Life sciences · Journal article
Phytotherapy Research · September 20, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
ABSTRACT Plant‐derived natural products have emerged as important sources of anticancer agents because of their diverse chemical structures and broad biological activities. However, their clinical application is often limited by poor aqueous solubility, low membrane permeability, insufficient tumor selectivity, and systemic toxicity. Recent advances in nanodelivery systems have provided effective strategies to overcome these pharmacokinetic and pharmacodynamic barriers by improving drug stability, enhancing tumor‐targeted accumulation, and promoting intracellular delivery. In this review, we systematically summarise recent progress in the nanotechnology‐based delivery of plant‐derived natural products for cancer therapy, with a focus on three major strategies: chemical conjugation, self‐assembly of natural products, and codelivery of natural products with chemotherapeutic agents. We further discuss the major advantages of these systems, including improved bioavailability, enhanced targeting capacity, reduced off‐target toxicity, and the potential to overcome multidrug resistance. Finally, current challenges in formulation design, safety evaluation, large‐scale manufacturing, and clinical translation are highlighted. This review provides a comprehensive framework for the rational development of plant‐derived natural product nanomedicines in precision oncology.